Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injections in opioid dependence
- Randomized, controlled study of Buvidal weekly and monthly subcutaneous depot injections vs daily sublingual buprenorphine
- The primary endpoint was met with statistically higher patient global satisfaction with the depot buprenorphine treatment
- Improved outcomes were also reported for secondary endpoints, including decreased treatment burden and higher quality of life
News provided by
Share this article
LUND, Sweden, May 10, 2021 /PRNewswire/ Camurus (NASDAQ STO: CAMX) announces today the publication in
JAMA Network Open of results from a 24-week, randomized, controlled trial (DEBUT) comparing patient reported outcomes of opioid dependence treatment with subcutaneous weekly and monthly buprenorphine depot injections (Buvidal
Opinion: Where does a lack of empathy lead us? – The Echo
echo.net.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from echo.net.au Daily Mail and Mail on Sunday newspapers.
New type of bone cell could reveal targets for osteoporosis treatment
unsw.edu.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from unsw.edu.au Daily Mail and Mail on Sunday newspapers.